Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Odette S ReifsniderPratik PimpleSarah BrandEvelien Bergrath WashingtonSharash ShettyNihar R DesaiPublished in: Diabetes, obesity & metabolism (2022)
For patients with T2D, use of second-line empagliflozin combined with metformin was a dominant strategy for US payers, associated with extended survival, improved QALYs, and lower costs compared with second-line liraglutide.